A new technology combining minute, lab-grown slivers of the human body with microchips is piquing the interest of pharmaceutical companies and health care investors in China, as it offers a new and potentially lucrative type of personalized care that could disrupt the traditional drug industry. So-called 'organoids' are three-dimensional (3D) in vitro models that are able to reproduce the cellular and molecular composition of living tissue, such as an organ or a tumor. These are the basis for the aptly named 'organoid-on-a-chip' technology.

https://www.caixinglobal.com/2023-07-28/in-depth-the-budding-market-for-microscopic-organ-testing-102087322.html

#caixinglobal